StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Biopharma Segment by Quarter

Biopharma Segment — Cost of sales (ASU 2023-07 significant expense) ($M) ($M)

QuarterlyAnnual

Pfizer Biopharma Segment: $3,188M in Q2 2026, up 3.7% from a year earlier.

Latest, Q2 2026
3,188
Period ended Jun 28, 2026
Change on a year earlier
+3.7%
3,075 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Note 17 — Segment Reporting (ASU 2023-07 Significant Segment Expenses).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBiopharma Segment — Cost of sales (ASU 2023-07 significant expense) ($M) ($M)Year on yearSource
Q2 2026Jun 28, 20263,188+3.7%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 29, 20263,034+31.1%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 20254,590-13.6%Form 10-K (filed 2026-02-26) ↗
Q3 2025Sep 28, 20253,526-23.8%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 29, 20253,075+27.5%Form 10-Q (filed 2026-08-04) ↗
Q1 2025Mar 30, 20252,314-12.4%Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 20245,313–Form 10-K (filed 2026-02-26) ↗
Q3 2024Sep 29, 20244,630–Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 20242,411–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20242,643–Form 10-Q (filed 2025-05-05) ↗

Cite this data

StockData. (2026). Pfizer Biopharma Segment ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/seg-cogs-bio

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.